Short Analysis provided by Squeeze Report. Recent News from (OTC: CSBR)
Champions Oncology to Present at The MicroCap Conference on April 10th in New York City at the Essex House HACKENSACK, N.J. , April 4, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will be presenting at this year... Source: PR Newswire Date: April, 04 2018 08:30 Blog Exposure - Lexicon Announced NDA and MAA Submissions for Sotagliflozin to Treat Adults with Type-1 Diabetes Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 28, 2018 / Active-Investors.com has just released a free research report on Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX ) ("Lexicon"). If you want access to this report all you need to do is sig... Source: ACCESSWIRE IA Date: March, 28 2018 07:10 Champions Oncology's (CSBR) CEO Ronnie Morris on Q3 2018 Results - Earnings Call Transcript Champions Oncology, Inc. (CSBR) Q3 2018 Earnings Conference Call March 15, 2018 4:30 PM ET Executives Ronnie Morris – Chief Executive Officer David Miller – Chief Financial Officer Analysts Joshua Horowitz – Equity Group Anthony Marchese – TriPoi... Source: SeekingAlpha Date: March, 15 2018 21:13 Champions Oncology reports Q3 results Champions Oncology (NASDAQ: CSBR ): Q3 EPS of $0.00 More news on: Champions Oncology, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ... Source: SeekingAlpha Date: March, 15 2018 16:43 Champions Oncology Reports Quarterly Revenue of $5.1 Million HACKENSACK, N.J. , March 15, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced its financial results for the third fiscal qua... Source: PR Newswire Date: March, 15 2018 16:01 Champions Oncology to Announce Third Quarter Financial Results on Thursday, March 15, 2018 HACKENSACK, N.J. , March 7, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced it will report its financial and operational re... Source: PR Newswire Date: March, 07 2018 08:30 Champions Oncology to Participate at the 30th Annual ROTH Conference HACKENSACK, N.J. , Feb. 26, 2018 /PRNewswire/ -- Champions Oncology, Inc. (Nasdaq: CSBR), engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that management will participate at the 30th An... Source: PR Newswire Date: February, 26 2018 08:30 Motivated Patients with ROS1 Cancer Initiate Global Research Study SAN CARLOS, Calif. and HACKENSACK, N.J. , Feb. 21, 2018 /PRNewswire/ -- The Addario Lung Cancer Medical Institute (ALCMI), Champions Oncology (NASDAQ: CSBR) and the ROS1ders announce the commencement of a global study to gain a deeper understanding of ROS1-positive cancer. Th... Source: PR Newswire Date: February, 21 2018 08:30 Blog Exposure - FDA Granted Tentative Approval for Expanded Label for Egalet's ARYMO ER Extended-Release Tablets C-II Stock Monitor: Champions Oncology Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 18, 2017 / Active-Investors issued a free report on Egalet Corp. (NASDAQ: EGLT ), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=EGLT as t... Source: ACCESSWIRE IA Date: December, 18 2017 07:40 Champions Oncology's (CSBR) CEO Ronnie Morris on Q2 2018 Results - Earnings Call Transcript Champions Oncology, Inc. (CSBR) Q2 2018 Results Earnings Conference Call December 07, 2017 04:30 PM ET Executives Ronnie Morris - CEO David Miller - CFO Analysts Joshua Horowitz - Palm Small Cap Funds Presentation Operator Good day, ladies and gentlemen. And welcome... Source: SeekingAlpha Date: December, 07 2017 18:24 Last 5 Days Trading Activity
Date Open Price Close Price High Low Volume 2018-04-23 4.05 3.8742 4.0552 3.8742 12,632 2018-04-22 4.08 4.08 4.08 4.08 206 2018-04-21 4.08 4.08 4.08 4.08 206 2018-04-20 4.08 4.08 4.08 4.08 206 2018-04-19 3.73 4.08 4.08 3.73 2,729 Last 5 Days Short Activity
Date Short Volume Total Volume Short Percentage Short Indicator
Champions Oncology, Inc. the Company , is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs. The Company s TumorGraft Technology Platform is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune deficient mice. The Company uses this technology, in conjunction with related services, to offer solutions for two consumer groups: Personalized Oncology Solutions POS and Translational Oncology Solutions TOS . POS assists physicians in developing personalized treatment options for their cancer patients through tumor specific data obtained from drug panels and related personalized oncology services. The Company s TOS business offers a technology platform to pharmaceutical and biotechnology companies using proprietary TumorGraft studies, which the Company believes may be predictive of how drugs may perform in clinical settings.
 
 
 
Quarterly report with a continuing view of a company's financial position | ||
Filing Type: 10-Q | Filing Source: edgar | |
Filing Date: March, 19 2018 |
Report of unscheduled material events or corporate changes. | ||
Filing Type: 8-K | Filing Source: edgar | |
Filing Date: March, 15 2018 |
Report of unscheduled material events or corporate changes. | ||
Filing Type: 8-K | Filing Source: edgar | |
Filing Date: March, 12 2018 |
Quarterly report with a continuing view of a company's financial position | ||
Filing Type: 10-Q | Filing Source: edgar | |
Filing Date: December, 15 2017 |
Report of unscheduled material events or corporate changes. | ||
Filing Type: 8-K | Filing Source: edgar | |
Filing Date: December, 07 2017 |
Report of unscheduled material events or corporate changes. | ||
Filing Type: 8-K | Filing Source: edgar | |
Filing Date: October, 16 2017 |
Report of unscheduled material events or corporate changes. | ||
Filing Type: 8-K | Filing Source: edgar | |
Filing Date: October, 04 2017 |
Report of unscheduled material events or corporate changes. | ||
Filing Type: 8-K | Filing Source: edgar | |
Filing Date: September, 14 2017 |
Quarterly report with a continuing view of a company's financial position | ||
Filing Type: 10-Q | Filing Source: edgar | |
Filing Date: September, 14 2017 |
Information for Proxy Statement under Rule 14a-101 | ||
Filing Type: DEFR14A | Filing Source: edgar | |
Filing Date: August, 31 2017 |
 
 
It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter     Stay tuned for daily updates and more on (OTC: CSBR)
More to come on (OTC: CSBR)
Do your DD and if you choose, be ready to go!
The Research: All source information contained in this email is from the public sources mentioned below.
Thank you Monsta Trader     Disclaimer: Monsta Trader publishes reports providing information on selected companies. Monsta Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. Monsta Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CSBR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Monsta Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. Monsta Trader does not own any shares of CSBR and does not buy, sell, or trade any shares of CSBR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by Monsta Trader. All rights reserved. Our Full Disclaimer: http://monstatrader.com/disclaimer/  
@MonstaTrader
If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us